Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://hamido864noo5.wikissl.com/user